Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-25-001195
Filing Date
2025-07-14
Accepted
2025-07-14 09:23:46
Documents
72
Period of Report
2025-05-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q lxrp_10q.htm   iXBRL 10-Q 1027095
2 CHANGE ORDER TO PROJECT AGREEMENT lxrp_ex102.htm EX-10.2 611373
3 CERTIFICATION lxrp_ex311.htm EX-31.1 12036
4 CERTIFICATION lxrp_ex312.htm EX-31.2 12547
5 CERTIFICATION lxrp_ex321.htm EX-32.1 6637
6 CERTIFICATION lxrp_ex322.htm EX-32.2 6567
12 lxrp_ex102img1.jpg GRAPHIC 3744
  Complete submission text file 0001640334-25-001195.txt   5742814

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20250531.xsd EX-101.SCH 50989
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20250531_lab.xml EX-101.LAB 294018
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20250531_cal.xml EX-101.CAL 46686
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20250531_pre.xml EX-101.PRE 244259
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20250531_def.xml EX-101.DEF 126406
75 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_10q_htm.xml XML 872397
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 001-39874 | Film No.: 251120290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)